Spermosens (SPERM) Q4 2024 earnings summary

Executive summary

• Achieved key milestones in clinical studies for JUNO-Checked technology, showing positive interim results and strong correlation with fertilization outcomes.

• Advanced commercialization strategy with new partnerships in Japan and the US, targeting the global sperm bank market.

• Implemented significant cost reductions and secured critical financing through rights and directed issues, supporting ongoing development.

• Focused on licensing agreements for scalable market entry and continued technical improvements to the JUNO-Checked system.

Financial highlights

• Net sales remained at SEK 0 for both Q4 and full year 2024, unchanged from 2023.

• Operating loss for the year improved to SEK -9,163k from SEK -10,873k year-over-year.

• Cash and cash equivalents at year-end were SEK 659k, down from SEK 4,492k in 2023.

• Equity increased to SEK 27,345k from SEK 12,692k, mainly due to capital raises.

• Earnings per share for the year were SEK -0.04, compared to SEK -0.32 in 2023.

Outlook and guidance

• Aims to complete the clinical study in 2025 and expects further engagement with global partners.

• Ongoing capital raise is critical to ensure going concern and support continued development.

• Anticipates value-triggering results from clinical studies and progress in partnership discussions in 2025.